Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
13.07
+0.08 (0.62%)
At close: Dec 5, 2025, 4:00 PM EST
12.60
-0.47 (-3.60%)
After-hours: Dec 5, 2025, 7:42 PM EST

Company Description

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates.

Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.

The company is headquartered in Waltham, Massachusetts.

Crescent Biopharma, Inc.
Crescent Biopharma logo
Country United States
Founded 2003
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Joshua Brumm

Contact Details

Address:
300 Fifth Avenue
Waltham, Massachusetts 02451
United States
Phone 617-430-5595
Website crescentbiopharma.com

Stock Details

Ticker Symbol CBIO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001124105
CUSIP Number 14888D208
ISIN Number KYG2545C1042
Employer ID 56-2020050
SIC Code 2834

Key Executives

Name Position
Joshua T. Brumm Chief Executive Officer and Director
Dr. Jonathan McNeill M.D. President and Chief Operating Officer
Richard William Scalzo M.B.A. Chief Financial Officer
Ryan Lynch Senior Vice President of Finance, Treasurer and Chief Accounting Officer
Dr. Jan Pinkas Ph.D. Chief Scientific Officer
Barbara H. Bispham J.D. General Counsel and Corporate Secretary
Amy Reilly Chief Communications Officer
Christopher Doughty Chief Business Officer
Dr. Wenjie Cheng Ph.D. Senior Vice President of Technical Operations
Dr. Ellie Im M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 13, 2025 144 Filing
Nov 7, 2025 10-Q Quarterly Report
Nov 7, 2025 8-K Current Report
Sep 10, 2025 8-K Current Report
Aug 22, 2025 8-K Current Report
Aug 11, 2025 10-Q Quarterly Report
Aug 11, 2025 8-K Current Report
Jun 6, 2025 8-K Current Report
May 23, 2025 8-K Current Report
May 23, 2025 424B5 Filing